Full Text PDF Similar Articles

¹İ.Ü. Onkoloji Enstitüsü Temel Onkoloji ABD, İstanbul
²İ.Ü. Onkoloji Enstitüsü Temel Onkoloji ABD Kanser Biyokimyası Bilim Dalı, İstanbul
³İ.Ü.Onkoloji Enstitüsü Prevantif Onkoloji ABD, İstanbul
⁴İ.Ü. Onkoloji Enstitüsü Klinik Onkoloji ABD, İstanbul
⁵İ.Ü. Onkoloji Enstitüsü We investigated the serum levels of an important protein, bcl-2, in 44 patients with malignant melanoma and the relationship with tumour progression and known prognostic parameters. Serum bcl-2 levels were determined using enzyme-linked immunosorbent assay (ELISA) (Biosource International, Inc. 542 Flynn Road Camarillo, California, USA). The baseline serum bcl-2 levels were significantly higher in patients with malignant melanoma than in the control group (p=0,01). The bcl-2 values were not changed with Interferon-alfa therapy (n=8) and chemotherapy (n=10).With this small study, it is not possible to determine the value of serum levels of bcl-2 in malignant melanoma and larger scale research studies are needed in this field. Keywords : malignant melanoma, bcl-2, serum